US 11840575
Engineered immune cells targeting BCMA and their uses thereof
granted A61KA61K2039/505A61K2239/28
Quick answer
US patent 11840575 (Engineered immune cells targeting BCMA and their uses thereof) held by GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD.
- Grant date
- Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 28
- CPC classes
- A61K, A61K2039/505, A61K2239/28, A61K2239/29, A61K2239/48